ExpreS2ion announces financial results for the second quarter of 2024
Hørsholm, Denmark, 15 August 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter and half-year financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments:“On the first of July, we announced the completion of a rights issue raising gross proceeds of SEK 30 million. With a cash position of SEK 68.6 million at the end of the second quarter, ExpreS2ion is funded to initiate the ES2B-C001 first-in-human Phase I trial, subject to